Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $27.9 million.

  • Adma Biologics' Change in Receivables rose 3955.16% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.5 million, marking a year-over-year increase of 36508.16%. This contributed to the annual value of $22.6 million for FY2024, which is 8947.63% up from last year.
  • Per Adma Biologics' latest filing, its Change in Receivables stood at $27.9 million for Q3 2025, which was up 3955.16% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Change in Receivables ranged from a high of $49.4 million in Q1 2025 and a low of -$19.5 million during Q2 2024
  • Moreover, its 5-year median value for Change in Receivables was $2.1 million (2021), whereas its average is $6.5 million.
  • In the last 5 years, Adma Biologics' Change in Receivables crashed by 165471.28% in 2021 and then surged by 47367.25% in 2023.
  • Over the past 5 years, Adma Biologics' Change in Receivables (Quarter) stood at $8.2 million in 2021, then plummeted by 165.95% to -$5.4 million in 2022, then grew by 27.78% to -$3.9 million in 2023, then skyrocketed by 96.38% to -$141000.0 in 2024, then soared by 19921.28% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $10.3 million for Q2 2025, and $49.4 million during Q1 2025.